Elvina Almuradova: Cemiplimab monotherapy vs chemotherapy as a first-line treatment with advanced NSCLC with PD-L1 expression
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared an article by Saadettin Kilickap, et al. on LinkedIn:
“The EMPOWER-Lung 1 trial, led by Prof. Dr. Saadettin Kilickap as the first author, assessed cemiplimab monotherapy versus chemotherapy as a first-line treatment in patients with advanced NSCLC with PD-L1 expression ≥50%.
A total of 712 patients were randomized to cemiplimab (n = 357) or chemotherapy (n = 355), with a median follow-up of 59.6 months.
Among patients with verified PD-L1 ≥50% (n = 565):
- Median OS was 26.1 months with cemiplimab vs. 13.3 months with chemotherapy (HR: 0.59, 95% CI: 0.48–0.72).
- Median PFS was 8.1 vs. 5.3 months (HR: 0.50, 95% CI: 0.41–0.61).
- Objective response rate (ORR) was 46.5% with cemiplimab vs. 20.6% with chemotherapy.
- 5-year OS probability was 29.0% with cemiplimab vs. 15.0% with chemotherapy.
The benefit was observed in both squamous and non-squamous histologies, with the greatest advantage seen in patients with PD-L1 ≥90%.
The safety profile remained consistent with prior findings. Grade ≥3 treatment-related adverse events occurred in 18.3% of cemiplimab-treated patients compared to 39.9% in the chemotherapy arm.”
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1.
Authors: Saadettin Kilickap, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023